Hartung HP - Search Results

1

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.

Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Könnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, Kümpfel T, Berger R, Röther J, Häußler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, Hümmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Among authors: hartung hp. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100. doi: 10.1212/NXI.0000000000001100. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34785575 Free PMC article.

2

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.

Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Kieseier BC, et al. Among authors: hartung hp. Muscle Nerve. 2004 Aug;30(2):131-56. doi: 10.1002/mus.20076. Muscle Nerve. 2004. PMID: 15266629 Review.

3

Towards individualised multiple-sclerosis therapy.

Gold R, Hartung HP. Gold R, et al. Among authors: hartung hp. Lancet Neurol. 2005 Nov;4(11):693-4. doi: 10.1016/S1474-4422(05)70205-2. Lancet Neurol. 2005. PMID: 16239174 No abstract available.

4

Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases.

Schneider-Gold C, Hartung HP, Gold R. Schneider-Gold C, et al. Among authors: hartung hp. Muscle Nerve. 2006 Sep;34(3):284-91. doi: 10.1002/mus.20543. Muscle Nerve. 2006. PMID: 16583368 Review.

5

Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis.

Albrecht P, Fröhlich R, Hartung HP, Kieseier BC, Methner A. Albrecht P, et al. Among authors: hartung hp. J Neurol. 2007 Nov;254(11):1595-6. doi: 10.1007/s00415-007-0538-3. Epub 2007 Nov 9. J Neurol. 2007. PMID: 17987252 No abstract available.

6

Intravenous immunoglobulins in the treatment of immune neuropathies.

Kieseier BC, Meyer Zu Hörste G, Lehmann HC, Gold R, Hartung HP. Kieseier BC, et al. Among authors: hartung hp. Curr Opin Neurol. 2008 Oct;21(5):555-62. doi: 10.1097/WCO.0b013e32830efc03. Curr Opin Neurol. 2008. PMID: 18769249 Review.

7

Persistence of immunopathological and radiological traits in multiple sclerosis.

König FB, Wildemann B, Nessler S, Zhou D, Hemmer B, Metz I, Hartung HP, Kieseier BC, Brück W. König FB, et al. Among authors: hartung hp. Arch Neurol. 2008 Nov;65(11):1527-32. doi: 10.1001/archneur.65.11.1527. Arch Neurol. 2008. PMID: 19001173

8

Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.

Aktas O, Hartung HP. Aktas O, et al. Among authors: hartung hp. J Neurol. 2009 Nov;256(11):1906-8. doi: 10.1007/s00415-009-5317-x. J Neurol. 2009. PMID: 19768482 No abstract available.

9

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hartung HP, Aktas O. Hartung HP, et al. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. Ann Neurol. 2009. PMID: 19847907 No abstract available.

10

Development of oral cladribine for the treatment of multiple sclerosis.

Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC. Hartung HP, et al. J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,136 results

Search Page

Filters